?? Welcome to The Biotech Beat: A Message From the Editor

When I created The Biotech Beat, my goal was simple: to bring the latest and most impactful developments in biotech to a community that shares my interest in life sciences innovation. As someone who has spent years involved in various aspects of this field - from academic research to life sciences investment banking to the biopharma C suite -?I have a unique appreciation for the complexity of this industry and the excitement, anxiety, and humility that it invokes. Today, I’m thrilled to see this community grow, with an audience of over 15,000 biotech financiers, industry professionals, and academic researchers who shape the future of the sector on a daily basis. To our long-time readers: thank you for being part of this journey. Your engagement and feedback have been the driving force behind The Biotech Beat. It’s because of you that this platform has become more than a newsletter—it’s a community that gives me consistent feedback and has nurtured more than a few friendships. ?

Today, I’d like to share a story that’s deeply personal to me — one that reoriented my arrow?and has imbued my life with great meaning.?

For those new to my story, my path to the biotech boardroom has been anything but traditional. After starting a PhD in biomedical engineering at Johns Hopkins, I eventually realized that my path lay outside the lab. I dropped out and moved from Baltimore to Boca Raton to pursue a career in investment banking. I didn’t even really know what investment banking was, but it sounded sexy. It was not. In another moment of epiphany (existential angst?) realized that being a financial intermediary was completely unstimulating. I yearned for a challenge that I could throw myself into, fully and wholly.? ?

Follow me on LinkedIn!

That opportunity came when, at the ripe old age of 27, I was offered the chance to take over Cytonics Corporation . On the brink of collapse, the company needed a fresh arm to throw a Hail Mary pass. They had nothing to lose, and neither did I.?Determined to turn things around, I quickly raised $1 million to reach our next drug discovery milestone and ignited a renewed interest in our drug development program for osteoarthritis.

The next 6 years were a blur of financings (with over $15M?via equity crowdfunding and a $40M raise planned for this year!), Research & Development (we’ve advanced our lead drug candidate into Phase 1 clinical trials), and professional maturation into a "real" executive.

Leading Cytonics has been the most challenging and rewarding experience of my life, and I feel immense gratitude for the chance to steer our groundbreaking work forward. Seven years into my tenure at the helm, I’m more committed than ever to fostering innovation and sharing the stories that shape our industry. That’s why The Biotech Beat matters: it’s a platform to highlight the breakthroughs, challenges, and opportunities that define our field. It also keeps me apprised of the latest developments in the industry?and potential partnership and financing opportunities that will benefit Cytonics. ?

In the coming weeks, I’ll share more about the Cytonics story… a tale rife with twists and turns, drama that contrasts starkly with the dispassion of science, and some fabulous failures that found redemption.

My hope is to not only inform but also inspire — because innovation thrives when people like you and me engage with and champion bold ideas. ?

?

Joey Bose is the President & CEO of Cytonics, a privately held biotechnology company that is developing The Holy Grail of Regenerative Medicine: a disease-modifying therapy for osteoarthritis. He holds a MSc in Biomedical Engineering from Johns Hopkins University, but would like to consider himself a halfway decent scribbler in addition to a scientist. In his free time he trains Brazilian Jiu Jitsu, enjoys kava, and plays with his pup.

Sincerely,

Joey Bose

President and CEO, Cytonics

[email protected]

This letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.?

Copyright ? 2025 Cytonics Corporation, All rights reserved.